Does Aetna (CVS Health) Cover Zepbound?

What Aetna's Default Position on Zepbound Is

Aetna (CVS Health) lists Zepbound as a covered drug on most commercial formularies, but coverage is not automatic. Prior authorization is required on every commercial plan reviewed as of mid-2025, and the PA criteria are detailed. Aetna places Zepbound in the specialty drug tier, which typically means the highest cost-sharing bracket, often 25-33% coinsurance after meeting a deductible.

The FDA approved tirzepatide (Zepbound) for chronic weight management in adults with a BMI of 30 kg/m² or greater, or 27 kg/m² or greater with at least one weight-related comorbidity such as hypertension, type 2 diabetes, or obstructive sleep apnea, in November 2023 [1]. Aetna's clinical policy mirrors that label language closely, but adds administrative layers that the FDA label does not require.

Coverage varies meaningfully between plan types. Fully insured Aetna commercial plans (where Aetna bears the insurance risk) follow Aetna's standard Clinical Policy Bulletin for weight-loss agents. Self-funded employer plans administered by Aetna may have customized benefit designs that exclude Zepbound entirely, regardless of medical necessity, because the employer sets the drug benefit, not Aetna. Always confirm your specific plan's Summary of Benefits and Coverage (SBC) or call the member services number on your insurance card before assuming coverage applies.

Medicare Part D plans administered by Aetna currently do not cover Zepbound for weight loss. The Medicare Modernization Act restricts Part D coverage of drugs used exclusively for weight loss [2]. The Treat and Reduce Obesity Act (TROA), if passed, would change this, but as of mid-2025 it has not been enacted.

What the Prior Authorization Criteria Require

Aetna's prior authorization for Zepbound is moderate-to-high in difficulty. Meeting every criterion requires coordinated documentation from the prescribing clinician, and missing even one element is enough for an initial denial.

The standard Aetna commercial PA criteria for Zepbound include all of the following:

BMI threshold. Documented BMI of 30 kg/m² or greater, or BMI of 27 kg/m² or greater with at least one qualifying comorbidity. Eligible comorbidities align with the FDA label and include hypertension, dyslipidemia, type 2 diabetes mellitus, and obstructive sleep apnea [1].

Diagnosis confirmed by a covered provider. The prescribing clinician must be a physician, nurse practitioner, or physician assistant operating within Aetna's network. Telehealth prescribers are accepted on many plans but must be credentialed.

Dietary and behavioral intervention. Aetna requires documentation that the patient has participated in a supervised diet and behavioral modification program for a minimum of six months before the PA is submitted on most plans. Records from a registered dietitian, a structured commercial weight-loss program, or documented physician counseling typically satisfy this requirement.

Absence of contraindications. The clinical notes must confirm no personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 (MEN2), consistent with the FDA boxed warning on the Zepbound prescribing information [1].

Concurrent GLP-1 or GIP exclusion. Aetna generally will not approve Zepbound alongside another GLP-1 receptor agonist such as semaglutide (Ozempic, Wegovy) or liraglutide (Saxenda). Approving both simultaneously is considered duplicative therapy.

Prescribers should submit chart notes covering at least the prior six months of weight-management efforts, a current height and weight with BMI calculation, a complete medication list, lab work including fasting glucose or HbA1c if diabetes is a listed comorbidity, and a letter of medical necessity. The Endocrine Society's 2023 clinical practice guideline on obesity pharmacotherapy states that "pharmacologic treatment of obesity should be integrated with behavioral intervention and continued only if the patient achieves at least 5% weight loss after 12-16 weeks of treatment" [3]. Citing that guideline language in the letter of medical necessity directly addresses Aetna's own benchmark for continued-use approvals.

How Step Therapy Works at Aetna for Zepbound

Step therapy adds another layer before Zepbound is approved. Most Aetna commercial formularies require that a member demonstrate an inadequate response or intolerance to at least one prior FDA-approved weight-loss agent before Zepbound is authorized.

Agents that typically satisfy Aetna's step-therapy requirement include orlistat 120 mg (Xenical), phentermine-topiramate ER (Qsymia), naltrexone-bupropion ER (Contrave), and liraglutide 3 mg (Saxenda). Some Aetna plan documents also accept documented intolerance rather than failure, meaning that if a patient could not tolerate liraglutide due to severe nausea, that record can substitute for a full trial. The clinician's note must describe the specific adverse effect, the dose at which it occurred, and the duration of the trial.

The SURMOUNT-1 trial (N=2,539) published in the New England Journal of Medicine demonstrated that tirzepatide 15 mg produced a mean body weight reduction of 20.9% at 72 weeks versus 3.1% for placebo (P<0.001) [4]. The 10 mg dose produced 19.5% weight reduction, and even the lowest dose of 2.5 mg titrated to 5 mg achieved 15.0% mean weight reduction at 72 weeks [4]. These results are substantially larger than those seen with older step-therapy agents. For comparison, the SCALE Obesity trial (N=3,731) showed liraglutide 3 mg produced 8.4% mean weight loss at 56 weeks [5]. The clinical gap between a first-step agent and tirzepatide is documented, and a prescriber can reference that gap in a medical necessity letter when step therapy feels clinically inappropriate for a specific patient.

Step therapy exceptions are possible. Under the Restoring the Patient's Voice Act and similar state-level step-therapy reform laws now enacted in more than 30 states, a prescriber can request an exception to step therapy if any of the following apply: the required step-therapy drug is contraindicated; the patient previously failed or was intolerant of the step agent; or the step-therapy drug is expected to cause adverse interactions with existing medications [6]. Documenting the specific statutory language of the applicable state law in the PA submission increases the probability of an exception being granted on first submission.

What Formulary Tier Zepbound Sits On

On Aetna commercial plans that cover Zepbound, it sits in the specialty tier, which is Tier 4 on a four-tier formulary or Tier 5 on a five-tier formulary. Specialty tiers typically carry the highest cost-sharing, most often expressed as a percentage coinsurance rather than a fixed copay.

A member with a plan that has 30% specialty coinsurance and a $4,500 individual deductible would owe the full list price of approximately $1,059 per month until the deductible is met, then roughly $318 per month in coinsurance afterward, assuming the plan's allowed amount aligns with list price. Out-of-pocket maximum provisions cap annual exposure, but the numbers are substantial before that cap is reached.

Aetna's CVS Caremark pharmacy benefit manager (PBM) negotiates a contracted rate with Eli Lilly that is lower than the $1,059 list price, but the plan's cost-sharing is typically calculated on the contracted rate, not the list price. The exact contracted rate is not publicly disclosed. Members should request the Explanation of Benefits (EOB) preview or use the Aetna member portal's drug cost estimator to see their specific cost share before filling the prescription.

The American Diabetes Association's 2024 Standards of Care note that "cost and access remain major barriers to GLP-1 receptor agonist and dual GIP/GLP-1 receptor agonist therapy" and recommend that clinicians and patients evaluate all available cost-reduction programs before abandoning an indicated treatment [7].

How to Appeal a Denied Zepbound Claim

Aetna denials of Zepbound follow a structured internal-then-external appeal pathway. A well-organized appeal reverses a significant proportion of initial denials.

Step 1: Request the denial letter and the coverage determination rationale. Aetna is required by the Affordable Care Act to provide a written denial that includes the specific clinical criteria the claim did not meet and the clinical reviewer's basis for the decision [8]. Read every line before drafting the appeal.

Step 2: File a first-level internal appeal within 180 days of the denial date. The appeal must include a letter of medical necessity from the prescribing clinician, peer-reviewed evidence supporting Zepbound's efficacy (SURMOUNT-1 is the strongest single citation [4]), any additional documentation the denial letter identified as missing, and a statement of the patient's clinical history with prior weight-loss interventions.

Step 3: Request an expedited appeal if medically urgent. If a clinician certifies that a standard 30-day appeal timeline would seriously jeopardize the patient's health, Aetna is required to decide within 72 hours under federal law [8].

Step 4: File a second-level internal appeal or request external independent review. If the first internal appeal is denied, most states allow or require Aetna to offer a second internal review. After exhausting internal options, the member can request an Independent Medical Review (IMR) through the state insurance commissioner's office. IMR overturns insurer denials at a meaningful rate across all drug classes, though tirzepatide-specific reversal data by insurer are not yet publicly available for 2024-2025.

Step 5: Contact your state insurance commissioner. Filing a complaint with the state department of insurance simultaneously with an external appeal creates a regulatory record and often prompts faster insurer action.

The American Heart Association's 2023 consensus statement on cardiovascular effects of obesity pharmacotherapy notes that "access barriers disproportionately affect patients with the highest cardiovascular risk" and recommends that clinicians "actively support patient appeals when evidence supports the indication" [9]. Including that statement in an appeal letter frames the denial as a patient safety issue rather than a cost-control measure.

Whether the Eli Lilly Savings Card Works with Aetna

The Lilly Savings Card for Zepbound can reduce out-of-pocket cost for eligible commercially insured patients to as low as $25 per month for a 1-month supply or $50 for a 3-month supply. However, manufacturer savings cards are generally not usable with federal government-funded insurance, including Medicare, Medicaid, CHIP, TRICARE, and the Federal Employees Health Benefits Program (FEHBP). Aetna commercial plans are eligible.

The practical interaction between the savings card and Aetna coverage is important to understand. When a member has a Zepbound PA approved, the savings card can be applied at the pharmacy to reduce the patient's coinsurance to the card's floor amount. The insurer still pays its contracted share, and the savings card covers the member's remaining cost-sharing up to the card's benefit limit. Lilly sets an annual cap on the savings card benefit. Members who anticipate high annual utilization should check the current terms at Lilly's official savings program page.

If Aetna denies coverage entirely, the savings card can still be used on a cash-pay basis at participating pharmacies, reducing the $1,059 list price to the savings card's promotional rate for eligible patients. CVS Pharmacy (Aetna's parent company) participates in the Lilly savings program. Using the card without going through insurance means the cost does not count toward the member's plan deductible or out-of-pocket maximum, which is a trade-off worth calculating for each individual's specific benefit design.

A 2024 analysis in JAMA Health Forum found that manufacturer copay assistance cards significantly reduce out-of-pocket costs for patients with commercial insurance but provide no benefit for publicly insured populations [10].

What the Clinical Evidence Means for the Coverage Conversation

The weight of evidence for tirzepatide's efficacy is now substantial, and referencing it precisely in PA submissions and appeals matters.

SURMOUNT-1 (N=2,539) showed 20.9% mean weight loss at 72 weeks with tirzepatide 15 mg versus 3.1% with placebo (P<0.001) [4]. SURMOUNT-2 (N=938), conducted in patients with type 2 diabetes, demonstrated 15.7% mean body weight reduction with tirzepatide 15 mg at 72 weeks versus 3.3% with placebo (P<0.001) [11]. The SURMOUNT-MMO cardiovascular outcomes trial (N=13,000+) is ongoing, but interim data and the SELECT trial for semaglutide support a cardioprotective signal for this drug class [12].

The FDA approved Zepbound in November 2023 based on the SURMOUNT trial program, with the prescribing information citing weight loss efficacy and an acceptable safety profile [1]. The Obesity Society's position statement states that "obesity is a chronic disease requiring long-term medical management" and supports pharmacotherapy as a first-line option alongside behavioral treatment for patients meeting BMI criteria [13]. That position statement is citable in an Aetna PA or appeal as a guideline-level endorsement of the treatment.

Clinicians submitting PA documentation for Aetna should specifically match the SURMOUNT-1 patient inclusion criteria (BMI 30 kg/m² or greater, or 27 kg/m² or greater with comorbidity) to the patient's chart data line by line. Aetna's reviewers compare the submitted record against the FDA label criteria, and any gap between the two is a denial risk.

Tirzepatide's mechanism as a dual GIP and GLP-1 receptor agonist distinguishes it pharmacologically from semaglutide (a GLP-1 receptor agonist only), and that distinction supports a separate clinical trial basis for coverage even on plans that previously approved and then discontinued semaglutide for a given patient [14].